Want to see PLRX full AI Analyst Report?
Pembrolizumab, Pln-101095
Advanced Or Metastatic Solid Tumor
Phase I
Recruiting
A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid Tumors
Jan 26, 2024
―
Pln-74809
Idiopathic Pulmonary Fibrosis
Phase II
Terminated
Randomized, Double-blind Study of Efficacy and Safety of Bexotegrast (PLN-74809) for Idiopathic Pulmonary Fibrosis
Oct 18, 2023
―
Pln-74809
Idiopathic Pulmonary Fibrosis
Phase II
Completed
Imaging Evaluation of PLN-74809 in Participants With IPF (PLN-74809)
Nov 02, 2022
―
Pln-74809
Primary Sclerosing Cholangitis
Phase II
Completed
Phase 2a Evaluation of Safety, Tolerability, and Pharmacokinetics of PLN-74809 in Patients With Primary Sclerosing Cholangitis (PSC)
Jul 13, 2020
―
FAQ
What are the FDA phases for drug approval?
The FDA approval process for new drugs is divided into several phases:
a. Preclinical testing
b. Phase 1 – Safety and dosage
c. Phase 2 – Effectiveness and side effects
d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments
e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
a. Preclinical testing
b. Phase 1 – Safety and dosage
c. Phase 2 – Effectiveness and side effects
d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments
e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
What is a clinical trial?
A clinical trial is a carefully designed study in which researchers test a drug, treatment, or medical device in people to evaluate its safety, effectiveness, and potential side effects. These trials are essential for determining whether a new treatment should be approved for widespread use.
What drugs does Pliant Therapeutics (PLRX) have in its pipeline
PLRX is currently developing the following drugs: Pembrolizumab, Pln-101095, Pln-74809, Pln-74809. These drug candidates are in various stages of clinical development as the company works toward FDA approval.